Cargando…
Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
OBJECTIVE: To estimate the cost-effectiveness of fluticasone propionate–salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD). STUDY DESIGN: Pooled economic analysis. METHODS: We performed an economic analysis of pooled dat...
Autores principales: | Dalal, Anand A, St Charles, Meaghan, Petersen, Hans V, Roberts, Melissa H, Blanchette, Christopher M, Manavi-Zieverink, Kathy |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921685/ https://www.ncbi.nlm.nih.gov/pubmed/20714371 |
Ejemplares similares
-
Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014) -
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010) -
Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
por: Dalal, Anand A, et al.
Publicado: (2012) -
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
por: Dalal, Anand A, et al.
Publicado: (2011) -
Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)